Company profile
DISC MEDICINE, INC.
NASDAQ:IRONBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BITOPERTIN | phase3 | — | 3 | active |
| SELCODEBART | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07187973 | phase1 | recruiting | 2026-01-06 | 2027-06-01 | Disc Medicine, Inc | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) |
| NCT06985147 | phase2 | active_not_recruiting | 2025-08-12 | 2027-02-01 | Disc Medicine, Inc | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) |
| NCT06050915 | phase1 | completed | 2023-10-03 | 2024-07-09 | Disc Medicine, Inc | A Study of DISC-3405 in Healthy Volunteers |
| NCT05883748 | phase2_3 | enrolling_by_invitation | 2023-08-31 | 2028-06-01 | Disc Medicine, Inc | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP |
| NCT06910358 | phase3 | completed | 2025-04-04 | 2026-09-08 | Disc Medicine, Inc | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
FDA applications (0)
No records yet.